229 results on '"Voß, F."'
Search Results
2. Effect of Cytomegalovirus Prophylaxis with Immunoglobulins or Antiviral Drugs on Lymphoproliferative Disease After Heart Transplantation: Single-Center Experience in 300 Patients
3. Heart Transplantation in Patients on Temporary Mechanical Circulatory Support
4. Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer
5. Validating available Donor-recipient risk assessment tools in a German Heart Transplant cohort
6. Impact of fast tacrolimus metabolizer status on outcome after heart transplantation
7. German Cardiac Arrest Registry (G-CAR): results of the pilot phase
8. POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
9. Gender-specific differences in young patients receiving implantable cardioverter-defibrillator therapy - a subgroup analysis of the german device registry
10. (656) Assessment of Risk Factors for Cytomegalovirus DNAemia after Termination of Regular Prophylaxes after Heart Transplantation
11. Impact of SARS-CoV-2 Infection on Reactivation of Herpesviridae after Heart and Heart and Kidney Transplantation
12. Subclinical Myocardial Leukocyte Infiltration after Covid-19-Vaccination in Heart-Transplant Recipients
13. Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4B, in Patients with Idiopathic Pulmonary Fibrosis: a Phase 2 Trial*
14. Sécurité d’emploi et efficacité de Bl 1015550, un inhibiteur préférentiel de la phosphodiestérase 4B (PDE4Bi), chez des patients atteints de fibrose pulmonaire idiopathique : essai de phase II
15. Subclinical Myocardial Leukocyte Infiltration after COVID-19 Vaccination in Heart-Transplant Recipients
16. 10-year follow-up of interventional electrophysiology: updated German survey during the COVID-19 pandemic
17. Procedure related complications following implantation of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) devices - Insights from the German DEVICE registry
18. Decline in forced vital capacity as a surrogate for mortality in patients with fibrosing interstitial lung diseases*
19. Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4b, in Patients with Idiopathic Pulmonary Fibrosis: A Phase 2 Trial
20. Minimally Invasive Surgical Ablation Combined with Postoperative Electrophysiological Evaluation and Intervention Is Highly Effective in the Treatment of Intermittent and Long-Standing Atrial Fibrillation
21. Decline in Forced Vital Capacity as a Surrogate for Mortality in Patients with Fibrosing Interstitial Lung Diseases
22. Optimal antithrombotic regimen in patients with cardiogenic shock on ImpellaTM mechanical support: less might be more
23. Study Design of a Phase III, Randomized, Placebo-Controlled Trial of Nintedanib in Children and Adolescents with Clinically Significant Fibrosing Interstitial Lung Disease (ILD)
24. Benefits of tiotropium/olodaterol compared with tiotropium in patients receiving COPD LAMA at baseline: pooled analysis of 4 clinical trials
25. Efficacy of tiotropium/olodaterol compared with tiotropium in patients naive to LAMA, LABA and ICS: Pooled analysis of four clinical trials
26. Mapping of desert locust habitats using remote sensing techniques
27. Towards a Sealed-Off Excimer Laser
28. S102 Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial
29. S29 The impact of GOLD stage on the effectiveness of tiotropium/olodaterol in preventing COPD exacerbations in the DYNAGITO trial
30. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium in Patients Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials
31. The Frequency of Exacerbations Treated with Antibiotics, Steroids or Both Differs by GOLD Stage in Patients with COPD in the DYNAGITO Trial
32. Treatment of First Exacerbation Predicts Future Risk of Exacerbations in Patients with COPD in the DYNAGITO Trial
33. The Impact of GOLD Stage on the Effectiveness of Tiotropium/Olodaterol in Preventing COPD Exacerbations in the DYNAGITO Trial
34. Seasonal Pattern of COPD Exacerbations in the DYNAGITO Trial
35. Konzept eines dezentralisierten Entwicklungs-Controlling
36. The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials
37. Classifying patients as GOLD A-D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials
38. Relative Timing of Clinically Important Deterioration and Related Long-Term Outcomes in COPD: A Post Hoc Analysis of the UPLIFT Study
39. Analysis of Rescue Medication Use over 1 Year in Patients Receiving LAMA, LABA, or Combination Maintenance Treatment for COPD in the TONADO Studies
40. Effects of Symptom Severity at Baseline on Lung-Funktion and SGRQ Responses in the OTEMTO Studies
41. Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B
42. Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
43. Tiotropium+olodaterol chez les patients atteints de BPCO modérée à sévère avec la bronchite chronique et/ou l’emphysème
44. P299 Effects of symptom severity at baseline on lung-function and sgrq responses in the otemto® studies
45. P295 Efficacy and safety of tiotropium/olodaterol in patients with copd by ats category
46. P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B
47. P55 Benefits of tiotropium/olodaterol on symptoms and health-related quality of life in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
48. P296 Effect of tiotropium/olodaterol therapy on copd exacerbations in the tonado® studies
49. P298 Tiotropium/olodaterol therapy provides symptomatic benefits irrespective of prior maintenance treatment: post hoc analyses of the otemto® studies
50. Prescription Patterns And Costs Of Migraine Therapy In Germany
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.